FRAMINGHAM, MA-Genzyme Corp. plans to develop a 300,000-sf manufacturing plant here next to the company's existing campus, which already includes manufacturing facilities, research and development laboratories and administrative offices. Construction is scheduled to begin this fall and the plant is expected to be operational by 2004.

The multi-million dollar plant is part of the biotechnology and health care products company's initiative to substantially expand its manufacturing capacity to support the growth of existing products and the launch of products within its development pipeline. The initiative calls for several major new facilities in the United States and Ireland to come on line over the next five years. The company currently operates 14 manufacturing facilities throughout the world.

“We are actively expanding our manufacturing capabilities in a comprehensive way in order to support our current and anticipated growth,” Henri A. Termeer, chairman and chief executive officer of Genzyme Corp. says in a released statement. “The investments we have made in our pipeline over the last several years are creating numerous opportunities to commercialize products in the near future.”

The facility here–which reportedly will employ over 300 people–will manufacture protein and antibodies. A new plant in Ireland will make Renagel, a kidney dialysis drug that is one of the company's newer and fast growing products.

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM Digital Member, you’ll receive:

  • Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.